CPB changes
Pick any two versions below to diff them.
- Price
- $20.38 → $19.37(−5.0%)
- Thesis
- removed: At $20.38, CPB trades below the analysts' intrinsic value. The market added: Campbell's is removed: worried about added: priced for a real, ongoing removed: decline: fiscal 2026 net added: decline, not just a rough patch. Both sales removed: fell 5% and removed: adjusted earnings removed: per share fell removed: 27% to $2.17, and management's added: in fiscal 2026. Management's own fiscal 2027 guidance calls for another removed: drop, with adjusted earnings per share of $1.65-$1.80. added: drop. To fund a turnaround, the board cut the removed: quarterly dividend 36%, to $0.25 per share, added: dividend, closed two snack plants, and removed: Campbell's cut about 550 removed: jobs and closed two snack plants as part of a new plan to save $500 million by fiscal 2030. added: jobs. Two rating agencies downgraded Campbell's debt within the past removed: year on the higher leverage, added: year, and both keep a negative outlook. removed: The case for added: For the removed: discount closing rests on that turnaround added: gap to close, the new $500 million cost-savings plan removed: working: cost savings flow through, added: must show up in results. Rao's and removed: Goldfish added: Goldfish, two of its brands, need to keep removed: growing, and the added: growing. The snacks business removed: stabilizes added: also needs to stabilize once the removed: new added: smaller plant footprint and lower headcount are added: fully in removed: place, letting margins recover from fiscal 2028 as management has signaled. added: place. Campbell's added: decades-old brands and removed: retailer relationships are the kind of moat that has let the company added: shelf space with big retailers have helped it survive weak stretches before. removed: The honest counter-case: leverage added: Management itself does not expect margins to recover until fiscal 2028, so this is removed: still elevated, at roughly added: not a quick fix. Leverage stays high for now, near 4.9 times adjusted removed: earnings by Moody's measure, GLP-1 drugs and private-label competition are structural pressures on both soup and snacks, and added: earnings, leaving little room for a added: setback. If the turnaround removed: that management itself now expects to take until added: holds through fiscal removed: 2028 added: 2027 results and into fiscal 2028, the gap could removed: easily slip further, leaving added: close by then. If leverage worsens or Rao's growth stalls, the removed: stock cheap for longer added: discount could persist or removed: forcing another dividend cut. added: widen.